One of the most common questions asked by emerging MedTech companies is: “What clinical data do we need for reimbursement in France?” At first glance, the question seems logical. However, it is often the wrong starting point.
In fact, successful MedTech reimbursement in France rarely begins with data. Instead, it begins with understanding which reimbursement pathway is most appropriate for the technology, the target population, and the intended go-to-market strategy.
Source: https://www.has-sante.fr/upload/docs/application/pdf/2009-12/guide_pratique_dm.pdf
Therefore, before discussing clinical endpoints, study design, or health economic evidence, companies should first determine where their technology fits within the French healthcare system.
Why reimbursement pathways drive evidence requirements
A common misconception is that France offers a single reimbursement process for medical devices. In reality, MedTech reimbursement in France is built around several distinct pathways, each with its own objectives, stakeholders, timelines, and evidence expectations.
Source: https://www.has-sante.fr/upload/docs/application/pdf/2010-03/guide_dm_gb_050310.pdf
Consequently, the level of clinical evidence required may vary significantly depending on the selected pathway. For example:
- First, LPPR reimbursement: the reference national reimbursement pathway for many medical devices. This pathway generally requires the strongest level of clinical evidence, ideally supported by randomized controlled trials. (HAS – Haute Autorité de Santé).
- Second, Intra-GHS funding: integration within existing hospital DRG budgets. Although reimbursement requirements may sometimes be lighter, hospitals face greater budget pressure, making adoption more challenging.
Source: https://www.has-sante.fr/upload/docs/application/pdf/2025-09/principes_devaluation_de_la_cnedimts_liste_des_produits_et_prestations_remboursables_lppr_ou_la_liste_positive_intra-ghs.pdf - Alternatively, PECT and PECAN pathways: temporary reimbursement mechanisms designed for innovative digital health technologies addressing unmet clinical needs while additional evidence is being generated.
Sources: https://www.has-sante.fr/upload/docs/application/pdf/2025-09/principes_devaluation_de_la_cnedimts_prise_en_charge_transitoire_pect.pdf, https://www.has-sante.fr/upload/docs/application/pdf/2025-09/principes_devaluation_de_la_cnedimts_prise_en_charge_anticipee_pecan.pdf - In addition, Forfait Innovation: an early funding mechanism intended to bridge important evidence gaps through structured clinical studies. (Ministère de la Santé français)
- Similarly, PHRC and PRME programs: academic funding initiatives that may help generate local clinical and medico-economic evidence while engaging key opinion leaders.
- Finally, Article 51 programs: experimental funding mechanisms supporting innovative care pathways and organizational transformation.
- Clearly, each pathway creates a different reimbursement strategy, a different evidence strategy, and a different go-to-market strategy.
Before discussing data, ask the uncomfortable questions
Too many companies start by discussing clinical trials before clarifying their strategic positioning. However, reimbursement success is rarely determined by evidence alone.
Instead, several fundamental questions should be addressed early:Is there a genuine unmet clinical need in France?
- Are competing technologies already reimbursed and widely adopted?
- What is the most relevant comparator in French clinical practice?
- What reimbursement level would be required to support long-term commercial viability?
- Is the target population sufficiently defined and clinically meaningful?
- Which physicians, KOLs, and reference centers are likely to drive future adoption?
Ultimately, these discussions often have a greater impact on reimbursement success than the statistical design of a future clinical study.
Strategic Perspective: reimbursement and go-to-market are inseparable
One lesson repeatedly observed in real-life MedTech projects is that reimbursement and go-to-market should never be managed independently. Indeed, the reimbursement pathway influences:
- the type of evidence to generate
- the timing of clinical studies
- the profile of investigators to engage
- the role of reference centers
- the pricing strategy
- the future commercial model
Therefore, reimbursement planning is not only a market access exercise. In fact, it is also a strategic go-to-market decision. As a result, companies that align these elements early generally move faster, reduce uncertainty, and create stronger adoption momentum once reimbursement discussions begin.
Field Perspective: early adoption often starts before reimbursement
In practice, some of the most successful MedTech market entries in France begin long before formal reimbursement is obtained. For instance, early interactions with KOLs and reference centers often help validate:
- patient selection criteria
- treatment positioning
- procedural workflows
- organizational impact
- future evidence generation priorities
Furthermore, these early adopters frequently become important contributors to future reimbursement discussions. This is particularly relevant because French authorities evaluate not only clinical outcomes but also the relevance of a technology within real-world clinical practice. As a result, building an early community of users can strengthen both reimbursement and go-to-market execution.
Strategic Implications
For international MedTech companies, the first reimbursement question should not be: “What data do we need?” Instead, it should be: “Which pathway are we pursuing, and what evidence, adoption strategy, and go-to-market model will support that pathway?”
To be precise, the answer to this question will shape virtually every subsequent decision. From clinical development to KOL engagement, from pricing expectations to commercial execution, reimbursement pathways create the framework within which market entry will ultimately succeed or fail.
Strategic Takeaway
Successful MedTech reimbursement in France does not start with a clinical study. Instead, it starts with choosing the right pathway. After all, data only become valuable when they answer the right reimbursement question.
And the right reimbursement question depends on the pathway you choose and the go-to-market strategy you intend to build. Consequently, entering France requires more than clinical evidence. Caredis helps international MedTech companies align reimbursement strategy, go-to-market execution, and hospital adoption from the earliest stages.
Related subject on this site: https://www.caredis.fr/tactical-collaboration-for-execution-on-the-field-services/; https://www.caredis.fr/medtech-reimbursement-in-france/, https://www.caredis.fr/medtech-market-entry-in-france/; https://www.caredis.fr/medtech-reimbursement-in-france/
